Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

VectivBio Holding AG (VECT)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.23+0.77 (+14.17%)
At close: 03:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.30
Open6.42
Bid2.17 x 1000
Ask7.50 x 900
Day's Range5.40 - 6.23
52 Week Range2.74 - 16.75
Volume3,006
Avg. Volume15,923
Market Cap223.552M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.58
Earnings DateNov 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.75
  • GlobeNewswire

    VectivBio to Participate at the Bank of America 2022 Healthcare Conference

    BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in Las Vegas, NV. Company management will also be participating in one-on-one investor meetin

  • GlobeNewswire

    VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications

    Arena Pharmaceuticals and Actelion veteran brings deep industry experience as VectivBio prepares for key upcoming catalystsBASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the appointment of Patrick Malloy as Senior Vice President, Investor Relations and Strategic Communications. Mr. Malloy’s two decades of in

  • GlobeNewswire

    VectivBio Reports Full Year 2021 Financial Results and Provides Business Update

    Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) On-Track for Topline Results at End of 2023 Cash Runway Extends Beyond Anticipated Release of Topline STARS Phase 3 Data Management to Host Conference Call Today at 8.00 a.m. ET BASEL, Switzerland, April 07, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceut

Advertisement
Advertisement